Zimmer Biomet (NYSE:ZBH) Updates FY 2025 Earnings Guidance

Zimmer Biomet (NYSE:ZBH) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided EPS guidance of 8.150-8.350 for the period, compared to the consensus EPS estimate of 8.550. The company issued revenue guidance of $7.8 billion-$7.9 billion, compared to the consensus revenue estimate of $8.0 billion.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. Barclays reduced their price target on shares of Zimmer Biomet from $125.00 to $118.00 and set an “underweight” rating on the stock in a research note on Thursday, December 12th. Oppenheimer decreased their price target on Zimmer Biomet from $145.00 to $135.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 15th. Stifel Nicolaus boosted their price objective on Zimmer Biomet from $130.00 to $138.00 and gave the company a “buy” rating in a report on Thursday, January 23rd. JMP Securities reaffirmed a “market outperform” rating and issued a $140.00 target price on shares of Zimmer Biomet in a research report on Friday. Finally, Royal Bank of Canada increased their price target on shares of Zimmer Biomet from $120.00 to $125.00 and gave the stock an “outperform” rating in a research report on Monday, November 4th. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and ten have given a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $124.70.

Zimmer Biomet Price Performance

ZBH traded down $1.24 during trading on Friday, reaching $101.45. 1,302,677 shares of the stock were exchanged, compared to its average volume of 1,777,397. Zimmer Biomet has a 1 year low of $100.67 and a 1 year high of $133.90. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.36 and a quick ratio of 0.70. The business’s 50 day moving average price is $107.56 and its two-hundred day moving average price is $108.16. The company has a market capitalization of $20.20 billion, a price-to-earnings ratio of 19.27, a P/E/G ratio of 1.88 and a beta of 1.02.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. During the same quarter in the prior year, the company posted $2.20 earnings per share. As a group, equities research analysts anticipate that Zimmer Biomet will post 7.99 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, January 31st. Shareholders of record on Monday, December 30th were paid a $0.24 dividend. The ex-dividend date was Monday, December 30th. This represents a $0.96 annualized dividend and a yield of 0.95%. Zimmer Biomet’s payout ratio is currently 18.25%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.